Improving assessment of prostate cancer bone metastases using advanced diffusion imaging

项目摘要 转移性前列腺癌（PCa）是一种使人衰弱且通常致命的疾病，影响数万人 在美国和全世界的男性中。存在有效的治疗选择以缓解症状和控制 癌症，其他人正在进行测试。甚至有人认为，如果我们能够 检测转移性疾病时，它是有限的，只有少数的位置。然而，治疗和 新疗法的测试需要转移的精确成像。不幸的是，大多数前列腺癌转移 在骨中，其中成像质量差，并且转移被认为是用常规方法不可测量的。 技术.这个项目的主要目标是优化和测试创新的方法，以定量 PCa的成像、辐射靶向和反应评估。该建议的核心是失真校正 和先进的扩散MRI模型，这是有效的检测PCa病变，并已显示 与临床结果有良好的相关性。 该提案的第一个具体目标是将失真校正的扩散MRI实施到一个 放射治疗计划系统，并测量畸变校正对精确和 骨转移瘤的准确肿瘤描绘。第二个目的是评估扩散的预后价值 MRI指标作为骨转移放疗后临床结局的预测因子， 在某些寡转移患者中存在生存获益的证据，对以下患者的生活质量具有重要意义： 疼痛性骨损伤第三个目的是评估扩散MRI定量治疗的可靠性 个体骨转移的缓解评估，临床实践和临床试验的未满足需求。 Seibert博士是放射医学和生物工程的助理教授， 关心这个建议，并提高其他研究人员的能力，更有效地测试实验 治疗PCa。同时，Seibert博士将获得作为主要研究者的指导经验， 凭借他的工程、临床和成像背景， PCa评估的定量工具。加州大学圣地亚哥分校和多模态成像和遗传学中心- 由K 08提案导师Dale博士指导，为这个项目和职业生涯提供理想的环境 发展，拥有经验丰富的导师团队和丰富的资源和熟练的人员，以促进 成功地完成了具体的目标，并启动了塞伯特博士的职业生涯作为一个物理学家，科学家， 放射肿瘤学和生物医学成像。

Project Summary Metastatic prostate cancer (PCa) is a debilitating and often deadly disease affecting tens of thousands of men in the U.S. and worldwide. Effective therapeutic options exist for symptom relief and control of the cancer, with others in the pipeline for testing. It is even thought that some patients might be cured if we could detect metastatic disease when it is limited to only a small number of locations. However, both treatment and testing of novel therapies require accurate imaging of the metastases. Unfortunately, most PCa metastases are in bones, where imaging quality is poor, and metastases are considered unmeasurable with conventional techniques. The broad goal of this project is to optimize and test innovative approaches to quantitative imaging, radiation targeting, and response assessment of PCa. The proposal centers on distortion correction and advanced diffusion MRI models, which are effective for detection of PCa lesions and have shown promising association with clinical outcomes. The first specific aim of the proposal is to implement distortion-corrected diffusion MRI into a radiotherapy treatment planning system and measure the impact of distortion correction on precise and accurate tumor delineation in bone metastases. The second aim is to evaluate the prognostic value of diffusion MRI metrics as predictors of clinical outcomes after radiotherapy for bone metastases, a treatment with evidence of a survival benefit in some oligometastatic patients and important for quality of life in patients with painful bone lesions. The third aim is to evaluate the reliability of diffusion MRI for quantitative treatment response assessment of individual bone metastases, an unmet need for clinical practice and clinical trials. Dr. Seibert, assistant professor of Radiation Medicine and Bioengineering, seeks to advance patient care with this proposal and to improve the ability of other investigators to more efficiently test experimental treatments for PCa. Simultaneously, Dr. Seibert will gain mentored experience as a principal investigator and build on his engineering, clinical, and imaging backgrounds with specific expertise in the development of quantitative tools for PCa assessment. UC San Diego and the Center for Multimodal Imaging and Genetics— directed by K08 proposal mentor, Dr. Dale—provide the ideal environment for this project and career development, with a veteran team of mentors and an abundance of resources and skilled personnel to facilitate successful completion of the specific aims and to launch Dr. Seibert’s career as a physician-scientist in radiation oncology and biomedical imaging.